Phase 3 Pulmonary Hypertension Trial, Recruiting NCT06646653 Sponsor: ResQ Medical Ltd Condition: Pulmonary Hypertension
Back to Pulmonary Hypertension

Phase 3 Pulmonary Hypertension Trial, Recruiting

NCT06646653
Recruiting Phase 3

Who may be able to join

AI generated eligibility summary. Written by an AI model from the official source data and checked on a sample basis. It can contain mistakes, so confirm anything important against the original source. How we use AI

Who might be able to join this trial:

  • You are a woman aged 18 or older at the time of agreeing to participate.
  • You are able to understand the study information and agree to take part.
  • You have been diagnosed with abnormal heavy bleeding from the uterus after giving birth (either vaginally or by C-section), suspected to be caused by the uterus not contracting properly, within 24 hours of delivery.
  • Your estimated blood loss falls within a specific range: between 500–1,500 ml for a vaginal delivery, or between 1,000–1,500 ml for a C-section, measured at the time the study device is about to be used.
  • Standard first-line treatments to stop the bleeding (medications to help the uterus contract and uterine massage) have already been tried but have not stopped the bleeding.

Who may not be able to join:

  • Your estimated blood loss is more than 1,500 ml at the time the study device is about to be used.
  • Your baby was born before 34 weeks of pregnancy.
  • You had a C-section and your cervix was less than 3 cm open before the device would be used.
  • Your doctor determines your bleeding requires more aggressive treatment, such as removal of the uterus, certain surgical stitching procedures, blocking or tying off specific blood vessels in the uterus or pelvis.
  • You have a known abnormality in the shape or structure of your uterus.
  • There is still an ongoing pregnancy in the uterus.
  • You have a known problem with how the placenta attached or was delivered, including abnormal attachment, a retained placenta with known risk factors, or a retained placenta that cannot be easily removed by hand.
  • You have a known tear or rupture of the uterus.
  • You have an unresolved uterine inversion (where the uterus has turned inside out and has not been corrected).
  • You have already received a balloon, packing, or another suction-based treatment inside the uterus for this episode of heavy bleeding before the study device would be used.
  • You currently have cervical cancer.
  • You currently have an active purulent (pus-forming) infection of the vagina, cervix, or uterus.
  • You have been diagnosed with a blood clotting disorder.

Important: Always verify eligibility with the trial site directly before applying.

Based on publicly available eligibility criteria from ClinicalTrials.gov. Verify directly with the trial site before acting. This is not medical advice.

This is a simplified plain English summary of the eligibility criteria. Full criteria are set by the trial investigators and may include additional requirements not shown here. Never self-exclude from a trial based on this summary. Contact the trial site directly to confirm your eligibility.
Last synced 26 July 2026
Phase 3: approximately ~65% of drugs entering this phase reach regulatory approval, based on published industry-wide historical data. This is not specific to this trial.
Phase success rates shown are historical industry-wide averages based on published data. They are not a prediction for this specific trial or your individual situation.

Contact this trial

Principal Investigator: Scott Chudnoff, MD, Maimonides Medical Center

Phone: 972-548106010

Contact details sourced from ClinicalTrials.gov. Verify directly with the trial site before attending.

GP referral letter

Print a one-page summary to share with your doctor.

Trial details

Status
Recruiting
Phase
Phase 3
Sponsor
ResQ Medical Ltd
Registry
ClinicalTrials.gov
Start date
11 January 2026
Est. completion
1 January 2027

Where this trial is recruiting

🇮🇱 Israel 🇺🇸 United States

Primary endpoints

Incidence of safety events; PPH control

Can't join this trial?

Expanded access pathways

If this trial is not available to you, other access pathways may exist. In Australia, the TGA Special Access Scheme allows access to unapproved therapeutic goods for individual patients.

TGA Special Access Scheme information

Find other recruiting trials on ClinicalTrials.gov

Data last synced from ClinicalTrials.gov: 26 July 2026. Trial status can change. Always verify current status directly with the trial site before making any decision.

Trial recruitment status can change without notice between our nightly data updates. Always contact the trial site directly to confirm current recruitment status before making any decisions or travel arrangements.

View original record on ClinicalTrials.gov